These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 25930159)

  • 21. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
    Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
    Prezioso C; Grimaldi A; Landi D; Nicoletti CG; Brazzini G; Piacentini F; Passerini S; Limongi D; Ciotti M; Palamara AT; Marfia GA; Pietropaolo V
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
    Frohman EM; Monaco MC; Remington G; Ryschkewitsch C; Jensen PN; Johnson K; Perkins M; Liebner J; Greenberg B; Monson N; Frohman TC; Douek D; Major EO
    JAMA Neurol; 2014 May; 71(5):596-602. PubMed ID: 24664166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
    J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
    Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
    Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
    PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
    J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.
    Dominguez-Mozo MI; Garcia-Montojo M; De Las Heras V; Garcia-Martinez A; Arias-Leal AM; Casanova I; Arroyo R; Alvarez-Lafuente R
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1277-86. PubMed ID: 23979860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies.
    Auer M; Borena W; Holm-von Laer D; Deisenhammer F
    J Med Virol; 2017 Jan; 89(1):3-9. PubMed ID: 27253624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-resolution melting analysis for mutation scanning in the non-coding control region of JC polyomavirus from patients with progressive multifocal leukoencephalopathy.
    Nakamichi K; Tajima S; Lim CK; Saijo M
    Arch Virol; 2014 Jul; 159(7):1687-96. PubMed ID: 24463953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
    Correia I; Jesus-Ribeiro J; Batista S; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
    J Clin Neurosci; 2017 Nov; 45():257-260. PubMed ID: 28844615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
    Miranda Acuña JA; Weinstock-Guttman B
    Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
    Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
    Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate.
    Gosert R; Kardas P; Major EO; Hirsch HH
    J Virol; 2010 Oct; 84(20):10448-56. PubMed ID: 20686041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
    Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity.
    Huppke P; Hummel H; Ellenberger D; Pfeifenbring S; Stark W; Huppke B; Brück W; Gärtner J
    Mult Scler; 2015 Apr; 21(4):382-7. PubMed ID: 25070674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.
    Barroso B; Miquel M; Marasescu R; Demasles S; Krim E; Bonnan M
    Mult Scler Relat Disord; 2015 Jul; 4(4):380-2. PubMed ID: 26195060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
    Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased prevalence of JC polyomavirus viruria was associated with arthritis/arthralgia in patients with systemic lupus erythematosus.
    Lu MC; Yin WY; Liu SQ; Koo M; Tung CH; Huang KY; Lai NS
    Lupus; 2015 Jun; 24(7):687-94. PubMed ID: 25406489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.